BHLHE22

Summary

BHLHE22 (basic helix-loop-helix family member e22, HGNC:11963) is a protein-coding gene on chromosome 8q12.3, encoding Class E basic helix-loop-helix protein 22 (Q8NFJ8). Inhibits DNA binding of TCF3/E47 homodimers and TCF3 (E47)/NEUROD1 heterodimers and acts as a strong repressor of Neurod1 and Myod-responsive genes, probably by heterodimerization with class a basic helix-loop-helix factors.

This gene encodes a protein that belongs to the basic helix-loop-helix (bHLH) family of transcription factors that regulate cell fate determination, proliferation, and differentiation. A similar protein in mouse is required for the development of the dorsal cochlear nuclei, and is thought to play a role in in the differentiation of neurons involved in sensory input. The mouse protein also functions in retinogenesis.

Source: NCBI Gene 27319 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 75 total — 3 likely-pathogenic
• MANE Select transcript: NM_152414

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11963
Approved symbol	BHLHE22
Name	basic helix-loop-helix family member e22
Location	8q12.3
Locus type	gene with protein product
Status	Approved
Aliases	CAGL85, Beta3
Ensembl gene	ENSG00000180828
Ensembl biotype	protein_coding
OMIM	613483
Entrez	27319

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000321870

RefSeq mRNA: 1 — MANE Select: NM_152414 NM_152414

CCDS: CCDS6179

Canonical transcript exons

ENST00000321870 — 1 exons

Exon	Start	End
ENSE00001242976	64580365	64583627

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 96.03.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.6470 / max 304.8931, expressed in 155 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
89141	0.7382	111
89138	0.5263	36
89143	0.1566	57
89142	0.1386	43
89140	0.0531	23
89139	0.0342	13

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	96.03	gold quality
cortical plate	UBERON:0005343	94.56	gold quality
ganglionic eminence	UBERON:0004023	93.85	gold quality
cerebellar vermis	UBERON:0004720	92.94	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.98	gold quality
primary visual cortex	UBERON:0002436	89.58	gold quality
middle temporal gyrus	UBERON:0002771	88.92	gold quality
endothelial cell	CL:0000115	86.22	gold quality
superficial temporal artery	UBERON:0001614	85.99	gold quality
occipital lobe	UBERON:0002021	85.82	gold quality
epithelial cell of pancreas	CL:0000083	85.44	silver quality
oocyte	CL:0000023	85.02	gold quality
Ammon’s horn	UBERON:0001954	84.45	gold quality
cerebellum	UBERON:0002037	83.15	gold quality
cerebellar cortex	UBERON:0002129	82.29	gold quality
right hemisphere of cerebellum	UBERON:0014890	82.21	gold quality
cerebellar hemisphere	UBERON:0002245	81.99	gold quality
visceral pleura	UBERON:0002401	80.69	gold quality
Brodmann (1909) area 46	UBERON:0006483	79.78	gold quality
amygdala	UBERON:0001876	78.92	gold quality
entorhinal cortex	UBERON:0002728	78.77	gold quality
temporal lobe	UBERON:0001871	78.69	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.36	gold quality
seminal vesicle	UBERON:0000998	77.32	gold quality
parietal pleura	UBERON:0002400	77.08	gold quality
postcentral gyrus	UBERON:0002581	75.37	gold quality
cerebral cortex	UBERON:0000956	74.51	gold quality
medial globus pallidus	UBERON:0002477	74.39	gold quality
parietal lobe	UBERON:0001872	73.40	gold quality
lower lobe of lung	UBERON:0008949	73.22	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	472.97
E-ANND-3	no	1.29

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
INS
PAX6	Repression

JASPAR motifs

Motif	Name	Family
MA0818.1	BHLHE22	Tal-related
MA0818.2	BHLHE22	Tal-related
MA1635.1	BHLHE22	Tal-related
MA1635.2	BHLHE22	Tal-related

JASPAR matrix evidence (PMIDs): PMID:22284184

Upstream regulators (CollecTRI, top): ATOH7, HOXA10

miRNA regulators (miRDB)

115 targeting BHLHE22, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514

Literature-anchored findings (GeneRIF, showing 4)

• Segregates with Duane syndrome. Brain-specific expression with the highest abundance in the cerebellum. (PMID:12213201)
• Rare variant association study of veteran twin whole-genomes links severe depression with a nonsynonymous change in the neuronal gene BHLHE22. (PMID:34664540)
• BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. (PMID:35806162)
• BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer. (PMID:36941015)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	bhlhe22	ENSDARG00000058039
mus_musculus	Bhlhe22	ENSMUSG00000025128
rattus_norvegicus	Bhlhe22	ENSRNOG00000021745
drosophila_melanogaster	amos	FBGN0003270
drosophila_melanogaster	ato	FBGN0010433
drosophila_melanogaster	tap	FBGN0015550
caenorhabditis_elegans		WBGENE00003018
caenorhabditis_elegans		WBGENE00003595

Paralogs (15): NEUROG3 (ENSG00000122859), NEUROD4 (ENSG00000123307), BHLHE23 (ENSG00000125533), NEUROD1 (ENSG00000162992), NEUROD6 (ENSG00000164600), ATOH8 (ENSG00000168874), NEUROD2 (ENSG00000171532), ATOH1 (ENSG00000172238), OLIG3 (ENSG00000177468), NEUROG2 (ENSG00000178403), ATOH7 (ENSG00000179774), BHLHA15 (ENSG00000180535), NEUROG1 (ENSG00000181965), OLIG1 (ENSG00000184221), OLIG2 (ENSG00000205927)

Protein

Protein identifiers

Class E basic helix-loop-helix protein 22 — Q8NFJ8 (reviewed: Q8NFJ8)

Alternative names: Class B basic helix-loop-helix protein 5, Trinucleotide repeat-containing gene 20 protein

All UniProt accessions (1): Q8NFJ8

UniProt curated annotations — full annotation on UniProt →

Function. Inhibits DNA binding of TCF3/E47 homodimers and TCF3 (E47)/NEUROD1 heterodimers and acts as a strong repressor of Neurod1 and Myod-responsive genes, probably by heterodimerization with class a basic helix-loop-helix factors. Despite the presence of an intact basic domain, does not bind to DNA. In the brain, may function as an area-specific transcription factor that regulates the postmitotic acquisition of area identities and elucidate the genetic hierarchy between progenitors and postmitotic neurons driving neocortical arealization. May be required for the survival of a specific population of inhibitory neurons in the superficial laminae of the spinal cord dorsal horn that may regulate pruritis. Seems to play a crucial role in the retinogenesis, in the specification of amacrine and bipolar subtypes. Forms with PRDM8 a transcriptional repressor complex controlling genes involved in neural development and neuronal differentiation.

Subunit / interactions. Interacts with PRDM8.

Subcellular location. Nucleus.

Tissue specificity. Brain-specific, with the highest expression in the cerebellum.

RefSeq proteins (1): NP_689627* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011598	bHLH_dom	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR050359	bHLH_transcription_factors	Family

Pfam: PF00010

UniProt features (8 total): region of interest 3, compositionally biased region 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFJ8-F1	60.10	0.19

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-9762293	Regulation of CDH11 gene transcription
R-HSA-1500931	Cell-Cell communication
R-HSA-418990	Adherens junctions interactions
R-HSA-421270	Cell-cell junction organization
R-HSA-446728	Cell junction organization
R-HSA-9759475	Regulation of CDH11 Expression and Function
R-HSA-9759476	Regulation of Homotypic Cell-Cell Adhesion
R-HSA-9764260	Regulation of Expression and Function of Type II Classical Cadherins

MSigDB gene sets: 185 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8_TCELL_DN, GCACCTT_MIR18A_MIR18B, BENPORATH_ES_WITH_H3K27ME3, STAEGE_EWING_FAMILY_TUMOR, CMYB_01, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, GOBP_NEUROGENESIS, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, AATGGAG_MIR136, SHEPARD_BMYB_MORPHOLINO_DN, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN

GO Biological Process (4): sensory organ development (GO:0007423), positive regulation of transcription by RNA polymerase II (GO:0045944), axon development (GO:0061564), nervous system development (GO:0007399)

GO Molecular Function (4): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), protein dimerization activity (GO:0046983), E-box binding (GO:0070888), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Regulation of CDH11 Expression and Function	1
Cell-cell junction organization	1
Cell junction organization	1
Cell-Cell communication	1
Regulation of Expression and Function of Type II Classical Cadherins	1
Adherens junctions interactions	1
Regulation of Homotypic Cell-Cell Adhesion	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
animal organ development	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
neuron projection development	1
system development	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
protein binding	1
RNA polymerase II cis-regulatory region sequence-specific DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1226 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BHLHE22	PRDM8	Q9NQV8	868
BHLHE22	AP3B1	O00203	728
BHLHE22	ITGB3BP	Q13352	663
BHLHE22	LAMP2	P13473	594
BHLHE22	VSX2	P58304	593
BHLHE22	GRPR	P30550	590
BHLHE22	BARHL2	Q9NY43	575
BHLHE22	CD63	P08962	574
BHLHE22	PAX6	P26367	568
BHLHE22	FOXN4	Q96NZ1	542
BHLHE22	TBR1	Q16650	529
BHLHE22	VSX1	Q9NZR4	515
BHLHE22	POU4F2	Q12837	507
BHLHE22	SLC17A6	Q9P2U8	500
BHLHE22	PRDM13	Q9H4Q3	499

IntAct

9 interactions, top by confidence:

A	B	Type	Score
BHLHE23	CSNK2A2	psi-mi:“MI:0914”(association)	0.620
CCL18	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370
	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370
IFNA16	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370
IFNA21	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370
IL2	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370
IL37	BHLHE22	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (4): BHLHE22 (Biochemical Activity), BHLHE22 (Affinity Capture-MS), BHLHE22 (Affinity Capture-Western), OTUD3 (Affinity Capture-Western)

ESM2 similar proteins: A2A9A2, A4QNP7, A6QQ94, A6YP92, A7M7C7, A7MB54, B5RHS5, M0R6D8, O09029, O35085, P28360, P41225, P43694, P46153, P50548, P78414, P78415, P79772, P81067, P81068, P84550, P84551, Q08369, Q0Q0E4, Q14549, Q14774, Q2I327, Q2MJB4, Q2VL84, Q2VL87, Q2VL88, Q2VWA4, Q3SZJ5, Q4AE28, Q61169, Q61345, Q6YHU8, Q71T09, Q76L87, Q7TQ40

Diamond homologs: A8E5T6, B6VQA1, O09029, O09105, O13125, O13126, O16867, O35437, O42202, O42606, O43680, O45489, O57598, O88940, O96004, O96642, P10627, P13903, P46581, P48985, P48986, P48987, P57100, P57101, P57102, P59101, P61295, P61296, P70447, P70562, P70595, P70660, P70661, P79765, P79766, P79782, P79920, P97832, Q08DI0, Q0V9X5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	3
Uncertain significance	68
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
4819976	NM_152414.5(BHLHE22):c.764T>G (p.Met255Arg)	Likely pathogenic
4819977	NM_152414.5(BHLHE22):c.221_260del (p.Gly74fs)	Likely pathogenic
4820273	NM_152414.5(BHLHE22):c.751G>C (p.Glu251Gln)	Likely pathogenic

SpliceAI

10 predictions. Top by Δscore:

Variant	Effect	Δscore
8:64580884:G:GT	donor_gain	0.5200
8:64580428:A:G	donor_gain	0.4300
8:64580615:G:T	donor_gain	0.3900
8:64580597:G:GT	donor_gain	0.3700
8:64581056:G:GT	donor_gain	0.3700
8:64581056:G:T	donor_gain	0.3700
8:64580642:G:T	donor_gain	0.3300
8:64580615:G:GT	donor_gain	0.3200
8:64581979:A:T	donor_gain	0.2800
8:64580426:G:A	donor_gain	0.2300

AlphaMissense

2433 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:64581524:T:C	L245P	1.000
8:64581530:T:A	I247N	1.000
8:64581530:T:C	I247T	1.000
8:64581530:T:G	I247S	1.000
8:64581532:A:G	N248D	1.000
8:64581534:T:A	N248K	1.000
8:64581534:T:G	N248K	1.000
8:64581535:G:C	A249P	1.000
8:64581539:G:C	R250P	1.000
8:64581541:G:A	E251K	1.000
8:64581542:A:C	E251A	1.000
8:64581542:A:G	E251G	1.000
8:64581542:A:T	E251V	1.000
8:64581543:G:C	E251D	1.000
8:64581543:G:T	E251D	1.000
8:64581544:C:A	R252S	1.000
8:64581544:C:T	R252C	1.000
8:64581545:G:C	R252P	1.000
8:64581548:G:C	R253P	1.000
8:64581550:C:G	R254G	1.000
8:64581550:C:T	R254W	1.000
8:64581551:G:C	R254P	1.000
8:64581553:A:G	M255V	1.000
8:64581554:T:A	M255K	1.000
8:64581554:T:C	M255T	1.000
8:64581554:T:G	M255R	1.000
8:64581555:G:A	M255I	1.000
8:64581555:G:C	M255I	1.000
8:64581555:G:T	M255I	1.000
8:64581556:C:A	H256N	1.000

dbSNP variants (sampled 300 via entrez): RS1000055368 (8:64580235 C>G), RS1000365268 (8:64582716 T>C), RS1000481390 (8:64583157 A>T), RS1000829920 (8:64579294 C>A,G,T), RS1001112078 (8:64578738 C>G,T), RS1003328548 (8:64581189 G>A,T), RS1004401583 (8:64580504 T>C), RS1004753456 (8:64580755 G>C,T), RS1005134427 (8:64583965 C>T), RS1007462969 (8:64578567 G>T), RS1007640276 (8:64579739 T>C), RS1008029376 (8:64581995 C>T), RS1009080831 (8:64583261 T>C), RS1009441595 (8:64583530 A>G), RS1009809092 (8:64579727 T>C,G)

Disease associations

OMIM: gene MIM:613483 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal dominant

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002701_27	Verbal declarative memory	3.000000e-06
GCST005951_62	Body mass index	2.000000e-11
GCST006940_169	Neurociticism	2.000000e-08
GCST007324_34	Adventurousness	3.000000e-08
GCST007325_65	General risk tolerance (MTAG)	6.000000e-18
GCST007329_8	Automobile speeding propensity	1.000000e-09
GCST007576_185	Chronotype	4.000000e-08
GCST008757_35	Alcohol consumption	2.000000e-09

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0004340	body mass index
EFO:0007660	neuroticism measurement
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	3
Diethylhexyl Phthalate	decreases expression, decreases methylation, increases abundance, increases methylation	2
bisphenol A	increases methylation	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance, increases methylation	1
sodium arsenite	affects methylation	1
CGP 52608	increases reaction, affects binding	1
entinostat	decreases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Catechin	affects cotreatment, decreases expression	1
Cytarabine	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Nickel	decreases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice